Chemotherapy has been the primary treatment option for Hodgkin’s lymphoma for many decades. Chemotherapy uses drugs to kill cancer cells or stop them from growing and dividing. The type and dosage of chemotherapy drugs depend on the stage of cancer and other factors. Some of the most common chemotherapy drugs used for Hodgkin's lymphoma are:
- ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine): This chemotherapy combination is considered a standard first-line hodgkin's lymphoma treatment. It is usually given in 2-4 cycles over a period of 2-6 months.
- BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone): This more intensive chemotherapy regimen may offer higher cure rates for advanced-stage Hodgkin's lymphoma compared to ABVD. However, it comes with more side effects.
- Brentuximab vedotin: This is an antibody-drug conjugate targeting the CD30 protein found on Hodgkin's lymphoma cells. It is approved for use in certain relapsed or refractory Hodgkin's lymphoma cases, usually in combination with chemotherapy drugs.
Radiation Therapy
Radiation therapy uses high-energy X-rays or other particles to kill cancer cells or damage their ability to grow and multiply. For Hodgkin's lymphoma, radiation therapy is mainly used after chemotherapy to destroy any remaining cancer cells and reduce the risk of recurrence. It may also be used as a primary treatment for early-stage Hodgkin's lymphoma. The radiation is focused directly on the lymph nodes and other areas affected by the disease.
Stem Cell Transplant
For patients with relapsed or refractory Hodgkin's lymphoma, stem cell transplantation may provide the best chance of long-term remission. There are two main types of stem cell transplants used for Hodgkin's lymphoma:
- Autologous stem cell transplant (ASCT): In this procedure, the patient's own stem cells are collected from their blood before high-dose chemotherapy is given to destroy any remaining cancer cells. The stem cells are then infused back into the patient to help rebuild the bone marrow and immune system once the chemotherapy is over.
- Allogeneic stem cell transplant: This uses stem cells from a matched donor rather than the patient's own stem cells. It offers the potential benefit of a graft-versus-lymphoma effect, where the donor immune cells help eliminate any remaining cancer. However, it also carries higher risks of transplant-related complications.
